News

For the Second Year, Alafair Biosciences Makes Inc. 5000, With Three-Year Revenue Growth of 597%

Alafair Biosciences Awarded Synthetic Implantable Products Agreement with Premier, Inc. for VersaWrap® Hydrogel Sheet

Alafair Biosciences Receives Innovative Technology Contract from Vizient for VersaWrap®

Alafair Biosciences reports record-breaking 2023 business results

Alafair Biosciences Ranks No. 54 on 2024 Inc. 5000 Regional Southwest's Fastest-Growing Private Companies, Posting 2-Year Revenue Growth of 234%

Alafair Biosciences Announces 12,000+ VersaWrap® Implants in Patients

Alafair Biosciences Selected to Exhibit VersaWrap at Vizient Innovative Technology Exchange

Alafair recognized as Austin’s Fast Growing Medical Device Company

Alafair Biosciences is Named a Best Place to Work by Austin Business Journal

Alafair Biosciences Announces VersaWrap® Sales Milestone

Alafair Enrolls Tenth Patient in Distal Radius Fracture Clinical Study

Alafair Enrolls First Patient in Hand Tendon Clinical Study

Eric Giza, MD, FACS Joins Alafair Biosciences Scientific & Clinical Advisory Board

Alafair Biosciences launches VersaWrap, a plant-based, non-collagen, bioresorbable interface for tendon and/or peripheral nerve

Alafair Biosciences appoints John Joyoprayitno as new President and CEO

Alafair Biosciences Receives 510(k) Clearance for VersaWrap® Nerve Protector

Alafair Biosciences Announces VersaWrap® Tendon Protector Sales Milestone

Alafair Biosciences Raises Over $7.2 Million in Series B/B-1 Financing

Alafair Biosciences Launches VersaWrap Tendon Protector

Alafair Biosciences Receives FDA 510(k) Clearance for VersaWrap Tendon Protector